Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
3
2
0
0
Clarus Therapeutics Holdings, Inc.
Share · US18271L1070 · CRXT (XNAS)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Clarus Therapeutics Holdings, Inc.
Analyst Grade Summary
No Price
Company Profile for Clarus Therapeutics Holdings, Inc. Share
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
Company Data
Name Clarus Therapeutics Holdings, Inc.
Company Clarus Therapeutics Holdings, Inc.
Symbol CRXT
Website
https://clarustherapeutics.com
Primary Exchange 
NASDAQ
NASDAQ
ISIN US18271L1070
Asset Class Share
Sector Healthcare
Industry Drug Manufacturers - General
Country United States of America
Currency USD
Employees 0,0 T
Address 555 Skokie Boulevard, 60062 Northbrook
IPO Date 2021-09-07
ID Changes
| Date | From | To |
|---|---|---|
| 10.09.2021 | BLUW | CRXT |
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ | CRXT |
More Shares
Investors who hold Clarus Therapeutics Holdings, Inc. also have the following shares in their portfolio:
